Evaluation of Pharmaceutical Care in Depressed Outpatients

Depression Clinical Trial

— depression  

Official title:

EVALUATION OF THE EFFECTIVENESS OF PHARMACEUTICAL CARE (DÁDER PROGRAM) IN DEPRESSED OUTPATIENTS TREATED WITH PSYCHOTROPIC

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01571973
• Other study ID #: SPPsicobio1Lu
• Status: Active, not recruiting
• Phase: N/A
• First received: April 3, 2012
• Last updated: April 4, 2012
• Start date: March 2010
• Est. completion date: May 2012

Study information

• Verified date: June 2011
• Source: Federal University of São Paulo
• Contact: n/a
• Is FDA regulated: No
• Health authority: Brazil: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

The study examines whether pharmacotherapeutic follow-up improves outcomes of treatment of depressed outpatients.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: May 2012
• Est. primary completion date: March 2012
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• women between 18 and 65 years, with diagnostic hypothesis of depression at the beginning of treatment or change in treatment unless 2 months (dosage or substance)

Exclusion Criteria:

• record of dependence on psychoactive substances, diagnosed schizophrenia,

• low education (illiterate) or cognitive impairment evident that compromise the completion of research instruments

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care

Related Conditions & MeSH terms

• Depression

Intervention

Procedure:
• pharmacotherapeutic follow-up
health education adjustment of dose improve compliance replacement of medication

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Federal University of São Paulo

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	depression level	evaluation depression level by Beck scale	six months	No
Secondary	anxiety level	evaluation anxiety level by Beck scale.	6 months	No
Secondary	compliance	evaluation antidepressive treatment compliance by Morisky scale	6 months	No